Contact
QR code for the current URL

Story Box-ID: 481615

Max Planck Institute for Molecular Genetics Ihnestr. 63 - 73 14195 Berlin, Germany http://www.ITFoM.eu
Contact Project Coordination +49 30 84131587
Company logo of Max Planck Institute for Molecular Genetics
Max Planck Institute for Molecular Genetics

IT Future of Medicine (ITFoM) – European Consortium to Build a “Virtual Patient” Model Meets in Berlin

(PresseBox) (Berlin, )
Future and Emerging Technologies (FET) Flagship pilot project IT Future of Medicine (ITFoM) meets in Berlin on 9-10 February 2012. The first full consortium meeting will bring together around 120 delegates from nearly 70 partner institutions comprising internationally acknowledged researchers from academia and industry to discuss the next steps towards building a ‘virtual patient’ model.

The ITFoM consortium, coordinated by Prof Dr Hans Lehrach from the Max Planck Institute for Molecular Genetics in Berlin, will discuss a ten years research program to create the ‘virtual patient’ model and to submit this proposal to the European Commission in the frame of the FET flagship program by the end of April 2012.

The vision of the ITFoM project is to build a personalised patient model, a ‘virtual patient‘. This ‘virtual patient’ will support clinicians and general practitioners in their decision-making for medical therapy, allowing them to choose the optimal treatment for each individual and predict future health risks. The basis for the ‘virtual patient’ model is data pertaining to the genetic make-up of an individual and data on their protein and metabolite levels, which are used as indicators for the health status of a patient. These molecular data will be combined in the model with anatomical and physiological data, and also with information about the life styles and environment of each patient. Decisions on specific medical treatments for patients will be based on data analysed by the model. ‘Virtual patients’ will support medical practitioners in choosing drugs with the optimal effect on the patient, and will drastically reduce unwanted or even harmful side-effects of drugs.

Media enquiries:
ITFoM Managing Office
Max Planck Institute for Molecular Genetics
Ihnestr. 63-73
14195 Berlin
Germany
Tel: +49 30 8413 1614
Email: itfom@molgen.mpg.de; webpage: www.itfom.eu

Max Planck Institute for Molecular Genetics

FET11:

Within the EU Framework Program for Research and Technological Development, Future and Emerging Technologies (FET) is funding frontier research based on radically new visions of what can be done and grounded in scientifically valid ideas.

FET Flagships are large-scale, science-driven and mission oriented initiatives that aim to achieve a visionary technological goal. The six FET Flagship Pilot Actions to be launched are:
- FuturICT - The FuturICT Knowledge Accelerator and Crisis-Relief System: Unleashing the Power of Information for a Sustainable Future.
- Graphene - Graphene Science and technology for ICT and beyond.
- Guardian Angels - Guardian Angels for a Smarter Planet.
- HBP - The Human Brain Project.
- ITFoM - IT Future of Medicine: a revolution in healthcare.
- RoboCom - Robot Companions for Citizens.

To prepare the launch of the FET Flagships, the 6 Pilot Actions are funded for a 12-month period starting in May 2011. In the second half of 2012 two of the Pilots will be selected and launched as full FET Flagship Initiatives in 2013.

Web: http://www.fet11.eu/

ICT & FP7:

Information and Communication Technologies (ICT) are critical to improve the competitiveness of European industry and to meet the demands of its society and economy.

The objective of ICT research under the EU's Seventh Framework Programme (FP7), the EU's chief tool for research funding between 2007-2013, is to improve the competitiveness of European industry - as well as to enable Europe to master and shape the future developments of these technologies so that the demands of its society and economy are met.

The EU Member States have earmarked a total of 9.1 billion Euros for funding ICT over the duration of FP7; making it the largest research theme in the Cooperation programme, which is itself the largest specific programme of FP7 (with 64% of the total budget).

Web: http://cordis.europa.eu/...

Max Planck Society:

The Max Planck Society is Germany's most successful research organisation. Since its establishment in 1948, no fewer than 17 Nobel laureates have emerged from the ranks of its scientists, putting it on a par with the best and most prestigious research institutions worldwide. The more than 13,000 publications each year in internationally renowned scientific journals are proof of the outstanding research work conducted at Max Planck Institutes - and many of those articles are among the most-cited publications in the relevant field.

The primary goal of the Max Planck Society is to promote research at its own institutes. It is not a government institution although it is funded to a large extent by the federal and state governments. The currently 80 Max Planck Institutes conduct basic research in the service of the general public in the natural sciences, life sciences, social sciences, and the humanities. Max Planck Institutes focus on research fields that are particularly innovative, or that are especially demanding in terms of funding or time requirements. And their research spectrum is continually evolving: new institutes are established to find answers to seminal, forward-looking scientific questions, while others are closed when, for example, their research field has been widely established at universities. This continuous renewal preserves the scope the Max Planck Society needs to react quickly to pioneering scientific developments.

Web: http://www.mpg.de/en

Max Planck Institute for Molecular Genetics:

Lead partner of the ITFoM, the Max Planck Institute for Molecular Genetics is dedicated to decoding the DNA of human beings and other organisms. The Institute's scientists study the function of genes and their role during development, from the fertilised egg to the embryo and on to the mature organism. They are particularly interested in genes that can trigger diseases when they malfunction. For a quick and precise analysis of the genetic material, the scientists rely on state-of-the-art sequencing devices, which can decode the entire genetic material of a human being within a few days. Special computer programs designed at the Institute help them to analyse and interpret the resulting data.

Web: http://www.molgen.mpg.de/

ITFoM Partners:

Full Partner Organizations:
- Max Planck Institute for Molecular Genetics
- Medical University of Graz
- University College London
- Vereniging voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek en Patientenzorg
- University of Manchester
- European Molecular Biology Laboratory
- Wellcome Trust Sanger Institute
- Kungliga Tekniska högskolan
- Imperial College London
- Maastricht University
- Consorzio Interuniversitario Risonanze Magnetiche di Metalloproteine Paramagnetiche (CIRMMP)
- International Prevention Research Institute
- Uppsala University
- University of Luxembourg / Luxembourg Centre for Systems Biomedicine
- University of Leicester
- ISC Intelligence in Science
- University of Auckland
- Universite de Geneve
- CENTRO NACIONAL DE ANÁLISIS GENÓMICO
- Siemens Aktiengesellschaft Oesterreich
- Alacris Theranostics GmbH
- Charite Universitätsmedizin Berlin
- Illumina
- Commissariat a l'energie atomique et aux energies alternatives

Associate Partner Organizations:
- Eidgenössische Technische Hochschule Zürich
- Ontario Institute for Cancer Research
- International Foundation for Computer Assisted Radiology and Surgery
- German Cancer Research Center
- The Microsoft Research - University of Trento Centre for Computational and Systems Biology
- IBM Research
- Roche Diagnostics
- Agilent Technology
- Life Technologies
- Bruker Daltonik
- AB SCIEX
- Intel GmbH
- Oxford Nanopore Technologies
- Bayer Healthcare
- Janssen Pharmaceutica
- Institute for the Digital Economy
- Harvard Medical School
- Dahlem Centre for Genome Research and Medical Systems Biology
- Tel Aviv University
- Xerox Research Centre Europe
- Oracle Corporation
- University of Genoa (IT)
- University of Tartu (EE)
- HealthSolve (UK)
- Institut Pasteur (FR)
- Max Planck Institute for Molecular Plant Physiology (DE)
- Vienna University of Technology (AT)
- VSB Technical University of Ostrava (CZ)
- Westfälische Wilhelms-Universität Münster (DE)
- Metanomics Health (DE)
- CertiCon a.s. (CZ)
- Dublin University (IR)
- Aalto University (FI)
- Athens University of Economics and Business (GR)
- SIVECO Romania (RO)
- Universität Klagenfurt (AT)
- University of Strathclyde (UK)
- UCD Systems Biology Ireland (IR)
- University of Copenhagen (DK)
- University of Edinburgh (UK)

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.